Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems

This cross-sectional study examines the use and sufficiency of US Food and Drug Administration (FDA) postmarket surveillance systems for further assessing serious risks found at product approval between 2016 and 2025.

Authors

Institutions

Publication Details

Journal
JAMA Internal Medicine
Published
2026-11-16
DOI
https://doi.org/10.1001/jamainternmed.2026.5774
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems

Reshma Ramachandran, Shaimaa Elshafie, Joseph S. Ross, Joshua David Wallach et al.
1 links
JAMA Internal Medicine
Pharmacovigilance and Adverse Drug Reactions
article

Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems

Reshma Ramachandran, Shaimaa Elshafie, Joseph S. Ross, Joshua David Wallach, Erfan Taherifard, Rou-Zhen Chen
article en

Abstract

This cross-sectional study examines the use and sufficiency of US Food and Drug Administration (FDA) postmarket surveillance systems for further assessing serious risks found at product approval between 2016 and 2025.

JAMA Internal Medicine
Yale New Haven Hospital (US), Emory University (US), Yale University (US)
Good health and well-being
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon